Business

Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation

Appoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer Both executives possess proven track records in strategic execution and deal-making and will help drive long-term value creation at Galapagos Mechelen, Belgium; July 23, 2025, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointments of Ms. Sooin Kwon as Chief Business Officer (CBO) and Mr. Dan Grossman as Chief Strategy Officer (CStO), effective August 4, 2025, further strengthening

articleLakefront BiotherapeuticsJuly 23, 20253/company/galapagos-nv-1/news/galapagos-bolster-leadership-team-with-seasoned-life-sciences-executives-to-accelerate-business-transformation
Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation

About this update from Lakefront Biotherapeutics

[{"type":"image","alt":"Galapagos NV","displaySize":"","headline":null,"caption":"Galapagos NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/231a79f212c8051361274fdd509bada9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/n2iAy9u_uXZxYevnIzv00A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/231a79f212c8051361274fdd509bada9","width":300,"height":55}},"lazy":false},{"type":"text","content":"Appoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer","length":88,"tagName":"p"},{"type":"text","content":"Both executives possess proven track records in strategic execution and deal-making and will help drive long-term value creation at Galapagos","length":141,"tagName":"p"},{"type":"text","content":"Mechelen, Belgium; July 23, 2025, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointments of Ms. Sooin Kwon as Chief Business Officer (CBO) and Mr. Dan Grossman as Chief Strategy Officer (CStO), effective August 4, 2025, further strengthening the Company’s leadership team. They will both report to Henry Gosebruch, CEO, and join the Company’s Management Committee.","length":396,"tagName":"p"},{"type":"text","content":"“We are excited to welcome Sooin and Dan to our senior leadership,” said Henry Gosebruch, CEO of Galapagos. “With their deep industry expertise and strong track record analyzing and executing strategic transactions, they will play a critical role in advancing Galapagos’ transformation, adding new pipeline assets via business development, and enhancing our impact on improving human health around the world. I look forward to working closely with them as we position Galapagos to build shareholder value.”","length":506,"tagName":"p"},{"type":"text","content":"Ms. Kwon is a strategic and financial advisor with nearly 30 years of experience guiding life sciences companies through strategic transformation and growth initiatives. Most recently, she was a Partner at MTS Health Partners where she led numerous strategic and financing transactions across the biotech and pharma landscape. Prior to that, she held senior roles in investment banking, asset management, equity research, and healthcare consulting. Sooin holds an MBA from Columbia Business School and ...

More updates from Lakefront Biotherapeutics

Dan GrossmanGalapagosHenry GosebruchSooin KwonChief Strategy OfficerColumbia Business Schoolbiopharmaceutical companiesChief Business Officerthe Companybusiness development